Pfizer COVID-19 Vaccine Booster Dose Approved for Individuals 5 to 11 Years Old

June 23, 2022

Effective for dates of service on or after May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series.

Providers may use administration code 0074A (immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose) for the booster dose.

More information can be found on the Pfizer-BioNTech COVID-19 Vaccine webpage. Updated provider manual sections will be released in a future Medi-Cal Update.